CollaGenex, URL/Mutual Settle Periostat Litigation; FDA Lawsuit Continues
Executive Summary
A CollaGenex lawsuit challenging FDA's classification of Periostat as an "antibiotic" will continue despite the company's settlement of related litigation with United Research Labs/Mutual Pharmaceutical
You may also be interested in...
CollaGenex Periostat Lawsuit Hinges On FDA “Antibiotic” Determination
A federal judge must determine whether CollaGenex' Periostat is properly classified as an "antibiotic" after preliminarily enjoining FDA from approving generic versions of doxycycline hyclate 20 mg
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials